The present invention relates to a stable pharmaceutical tablet formulation comprising 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-L-alanyl-L-alaninate (neladenoson bialanate) in the form of one of its salts, characterized in that it releases the active ingredient rapidly, and to processes for production thereof, to the use thereof as a medicament, and to the use thereof for prophylaxis and/or treatment of cardiovascular disorders, for example worsening chronic heart failure, heart failure with reduced or preserved (HFrEF or HFpEF), angina pectoris and ischaemic injury during an acute coronary syndrome.本發明關於一種穩定的醫藥錠劑配製物,包含2-{4-[2-({[2-(4-氯苯基)-1,3-噻唑-4-基]甲基}氫硫基)-3,5-二氰基-6-(吡咯啶-1-基)吡啶-4-基]苯氧基}乙基-L-丙胺醯基-L-丙胺酸酯(奈拉德松二丙胺酸酯,neladenoson bialanate)多種鹽形式之一者,特徵在於其迅速地釋放活性成分,及關於其製造方法、關於其作為藥物的用途、以及關於其用於預防及/或治療心血管疾患,例如惡化慢性心臟衰竭、併有減少或維持左心室射出分率(HFrEF或HFpEF)之心臟衰竭、心絞痛及急性冠狀動脈症候群期間之缺血性損傷。
